Skip to main content
Premium Trial:

Request an Annual Quote

Australian Court Approves Qiagen's Purchase of Cellestis Shares

NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.

Upon implementation of the Scheme, Cellestis shareholders will received cash consideration of A$3.80 ($3.90) per share, comprised of A$3.73 in cash from Qiagen for each Cellesis share, and a special dividend of A$.07 per Cellestis share, Qiagen said separately.

Cellestic said it is in the process of applying for suspension from the Australian Stock Exchange, which was expected to take effect at 7 p.m. EST today.

The acquisition of Cellestis by Qiagen was approved by Cellestis shareholders last week. Qiagen originally was to pay A$3.55 per share of Cellestis stock under the terms of the deal, but last month raised the price to A$3.80 per share.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.